1147998-34-2

Basic information

• Product Name: benzyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate
• Synonyms: benzyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate;Benzyl 4-((triMethylsilyl)oxy)-5,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 1147998-34-2
• Molecular Formula: C₁₆H₂₃NO₃Si
• Molecular Weight: 305.44422
• Mol File: 1147998-34-2.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: benzyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate(1147998-34-2)
• EPA Substance Registry System: benzyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate(1147998-34-2)

Safety Data

• Hazardous Substances Data: 1147998-34-2(Hazardous Substances Data)

Usage

General Description

Benzyl 4-(trimethylsilyloxy)-5,6-dihydropyridine-1(2H)-carboxylate is a chemical compound used in organic synthesis. It is a derivative of pyridine and is commonly used in the preparation of various pharmaceuticals and agrochemicals. The trimethylsilyloxy group serves as a protecting group for the carboxylate functionality, allowing for selective manipulation of the molecule during synthetic procedures. benzyl 4-(triMethylsilylo×y)-5,6-dihydropyridine-1(2H)-carbo×ylate is valuable in the field of medicinal chemistry and drug development, as well as in the production of fine chemicals. Its unique structure and reactivity make it a useful building block for the synthesis of complex organic molecules.

Upstream product

• 6099-86-1 cyclohexylmethyl chlorocarbonate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 955029-44-4 (syn)-3-fluoro-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 847041-34-3 benzyl (3R,4S)-4-[{[(2S)-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-(2,5-difluorophenyl)-2-phenyl-2,5-dihydro-1H-pyrrol-1-yl]carbonyl}(methyl)amino]-3-fluoropiperidine-1-carboxylate 
• 845256-80-6 C₁₄H₁₉FN₂O₂ 
• 845256-61-3 benzyl (3R,4S)-4-[(tert-butoxycarbonyl)(methyl)amino]-3-fluoropiperidine-1-carboxylate 
• 847041-33-2 benzyl (3S,4R)-4-[(tert-butoxycarbonyl)(methyl)amino]-3-fluoropiperidine-1-carboxylate 
• 845256-78-2 (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide 
• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 1610033-97-0 benzyl 4-((tert-butyldimethylsilyl)oxy)-3-fluoropiperidine-1-carboxylate 
• 1228631-27-3 benzyl 3-fluoro-4-hydroxypiperidine-1-carboxylate 

Relevant articles and documents

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.